The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of MK-2206 in combination with lapatinib in patients (pts) with advanced solid tumors.
Kari Braun Wisinski
No relevant relationships to disclose
Amye Tevaarwerk
No relevant relationships to disclose
Maria Bell
No relevant relationships to disclose
Mark E. Burkard
No relevant relationships to disclose
Jens C. Eickhoff
No relevant relationships to disclose
George Wilding
Research Funding - Merck
Noelle K. LoConte
No relevant relationships to disclose
Anne M. Traynor
No relevant relationships to disclose
Tien Hoang
Research Funding - Merck
Jennifer Heideman
No relevant relationships to disclose
Jill Kolesar
No relevant relationships to disclose
Glenn Liu
No relevant relationships to disclose